


Invesco China Health Care Equity Fd.Z / LU2305833829 / A2QP2S / Invesco Management

Last 05/16/2024¹	Country	Branch	Type of yield	Type
4.30 USD	China	Sector Health / Pharma	reinvestment	Equity Fund



Risk key figures

SRI 1 2 3 4 5 6 7

Mountain-View Funds Rating² EDA³

75

Yearly Performance

2023 -13.21%

2022 -31.01%

Master data		Conditions		Other figures	
Fund type	Single fund	Issue surcharge	5.00%	Minimum investment	USD 1,500.00
Category	Equity	Planned administr. fee	0.00%	Savings plan	-
Sub category	Sector Health / Pharma	Deposit fees	0.01%	UCITS / OGAW	Yes
Fund domicile	Luxembourg	Redemption charge	0.00%	Performance fee	0.00%
Tranch volume	-	Ongoing charges	-	Redeployment fee	0.00%
Total volume	(05/16/2024) EUR 516.57 mill.	Dividends		Investment company	
Launch date	3/3/2021	Invesco Management			
KESr report funds	Yes	An der Welle 5, 60322, Frankfurt am Main			
Business year start	29.02.	Germany			
Sustainability type	-	https://www.de.invesco.com			
Fund manager	Chris Liu, Kehong Jiang				

Performance	1M	6M	YTD	1Y	2Y	3Y	5Y	Since start
Performance	+5.91%	-10.42%	-9.09%	-22.38%	-16.50%	-59.32%	-	-57.00%
Performance p.a.	-	-	-	-22.33%	-8.61%	-25.90%	-	-23.15%
Sharpe ratio	5.98	-1.04	-1.07	-1.23	-0.49	-1.05	-	-0.94
Volatility	16.28%	22.81%	24.91%	21.39%	25.40%	28.20%	0.00%	28.61%
Worst month	-	-18.82%	-18.82%	-18.82%	-18.82%	-19.05%	0.00%	-19.05%
Best month	-	10.94%	10.94%	10.94%	15.24%	15.24%	0.00%	15.24%
Maximum loss	-2.71%	-26.65%	-22.29%	-33.94%	-42.18%	-67.06%	0.00%	-

Distribution permission

Austria, Germany, Switzerland

1 Important note on update status: The displayed date refers exclusively to the calculation of the NAV.

2 The Mountain-View Data Fund Rating calculates a comparative ranking for funds using yield, volatility and trend data. For more information visit [MVD Funds Rating](#)

3 Displays the Ethical-Dynamical Ratio calculated according to standard criteria. The maximum value is 100. For more information visit [EDA](#)

Invesco China Health Care Equity Fd.Z / LU2305833829 / A2QP2S / Invesco Management

Investment strategy


The Fund may use derivatives (complex instruments) to manage the Fund more efficiently, with the aim of reducing risk, reducing costs and/or generating additional capital or income. The Fund is actively managed and is not constrained by its benchmark, MSCI China A Onshore Health Care Index, which is used for comparison purposes. However, as the benchmark is a suitable proxy for the investment strategy, it is likely that some of the Fund's holdings are also components of the benchmark. As an actively managed fund, this overlap will change and this statement may be updated from time to time.

Investment goal


The objective of the Fund is to achieve long term capital growth. The Fund invests in Chinese healthcare companies listed on the Shanghai or Shenzhen Stock Exchanges, traded via Stock Connect as well as those listed or traded elsewhere, included Qualified Foreign Investors (QFI). The Fund invests in companies which are attractively valued and demonstrate sustainable growth, along with a strong business model and sound balance sheet. For the purposes of the Fund, healthcare companies include (but are not limited to) companies in the sectors of pharmaceuticals, biotechnology, healthcare services and medical technology and supplies.

Assessment Structure


Assets




Largest positions



Countries



Branches



Currencies

